SCHEMBL94356

SCHEMBL94356

[CH2]c1ccc(C(=O)Nc2ccc(NC(C)=O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.71
APBA1 Q02410 1/20 0.71
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
ALDH1A1 P00352 5/20 0.59
POLB P06746 2/20 0.59
HPGD P15428 1/20 0.59
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
MAPT P10636 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
PKM P14618 1/20 0.53
APEX1 P27695 1/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
AGER Q15109 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210697 0.90 CACNA1B (0.85) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL94598 0.89 KMT2A (0.59) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL95420 0.88 SMN1; SMN2 (0.67) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL94608 0.86 RAB9A (0.72) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL95456 0.85 NPC1 (0.58) CACNA1BAPBA1MEN1KMT2APOLB
SCHEMBL95844 0.85 RAB9A (0.81) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL13986883 0.85 CACNA1B (0.76) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL22461605 0.83 CACNA1B (0.79) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL22461604 0.83 CACNA1B (0.79) CACNA1BAPBA1MEN1KMT2AALDH1A1
SCHEMBL11676225 0.83 MEN1 (0.77) CACNA1BAPBA1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2007119600-A9 CARBAZOLE COMPOUND OTSUKA PHARMA CO LTD (JP) 2008-05-02 WO disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
WO-2007119600-A1 CARBAZOLE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB CACNA1B 3216/4885APBA1 854/4885MEN1 4401/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 CACNA1B 4478/4885APBA1 4074/4885MEN1 3912/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 CACNA1B 4478/4885APBA1 4074/4885MEN1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.